echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Two well-known pharmaceutical companies are working together on 5 billion new and improved drugs.

    Two well-known pharmaceutical companies are working together on 5 billion new and improved drugs.

    • Last Update: 2020-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    (Photo source: Synthesic Pharmaceuticals official WeChat) News shows that dositan gel beam is a new class 2.2 drug developed by Hetbio for the treatment of advanced malignant solid tumors, aimed at improving the effectiveness and safety of chemotherapy in cancer patients, is currently in the phase I. clinical trial stage, there is no domestic and foreign products of the same category.
    Under the terms of the agreement, Hytbio will receive a down payment, a research and development milestone and a sales credit payment, while Sonic Pharmaceuticals will pay an additional incentive based on the availance of Dorsey beams at home and abroad.
    First Sound Pharmaceuticals will be responsible for follow-up clinical research, registration and marketing of products, and will have the right to develop and commercialize all adaptations of Dorsey beams worldwide.
    s market share as a broad-spectrum anti-tumor drug has long attracted a new group of drug companies to explore it.
    data show that dosital is mainly applicable to breast cancer, non-small cell lung cancer, prostate cancer, stomach cancer, head and neck squamous cell carcinoma, plus the national health insurance varieties, clinical needs are greater.
    meters intranet data show that in China's urban public hospitals, county-level public hospitals, urban communities and township hospitals terminal chemical anti-tumor and immunomodulant products TOP20, Dossythai injections ranked second, sales in 2015 exceeded 4 billion yuan, and then showed a rising trend year by year.
    2019, the sales of injection dossytasai in China's public hospital market reached 4.4 billion yuan, of which Hengrui Pharmaceuticals has the highest market share, at 45%.
    analysis points out that Dorsey glue beam is a new drug release technology.
    injection with dorcytasi polymer beam is the physical wrap of dorcytasis using mPEG-PDLLA, prepared with a nuclear-shell structure of the injection dossythal polymer beam.
    compared with existing preparations, it has the effect of tissue passive targeting and efficiency reduction, while avoiding the allergic reactions of existing preparations, fluid retention and other toxic side effects, and has better clinical safety.
    industry view shows that, unlike the new chemical solid drug investment, high risk, difficult characteristics, the development of a new drug release system with low cost, short cycle, quick results and so on, and the major pharmaceutical giants have success stories to be found - such as AstraZeneca treatment of schizophrenia drug "Srecon" using slow release technology;
    Innovatory Drug Research and Development and Commercialization Capabilities Public information shows that Synthesic Pharmaceuticals was founded in 1995, is a rapid transition to innovation-driven companies, focusing on cancer, nerves, autoimmunity and other major diseases, currently has nearly 50 in different stages of development in the research and innovation products, including small molecule drugs, polymer drugs and TCAR cell therapy, of which more than 10 innovative pharmaceutical products in the clinical stage, has been submitted to the new drug declaration or has been approved.
    currently, the acoustic pharmaceutical tumor portfolio consists of five products, including four main products: Endo, JetBlue, Jeebery and Chinese Fluorine.
    this time with Hetbio, Sonic Pharmaceuticals is also intended to expand its presence in the field of oncology.
    hetbio is primarily focused on the innovative drug development and commercialization capabilities of the pioneering pharmaceutical industry.
    In addition to independent research and development, Servo Pharmaceuticals also advocates independent research and development and in-depth cooperation in research and development in parallel, which may also be an important background for the two sides to reach cooperation - Synth has been looking for potential opportunities for cooperation, and has established cooperative relations with domestic and foreign pharmaceutical companies and biotechnology companies, access to a number of varieties in China's development and commercialization of the exclusive rights.
    As for Haiobit's commercialization capabilities, data show that as of December 31, 2019, Synnod had more than 2,600 sales and marketing staff in 31 provinces and autonomous regions of China, covering about 1,900 level III hospitals nationwide, about 17,000 other hospitals and medical institutions, and more than 200 large national or regional pharmacies.
    Heitbio is mainly a biotechnology company engaged in new drug research and development, focusing on high barrier biocompatory polymer synthesis, polymer nano-carriers, new drug accessories research and nano-drug preparation research and development, research and development pipeline including dositan gel beam and other high-barrier anti-tumor drugs.
    note that, in addition to the acoustic pharmaceutical industry, there are also a number of pharmaceutical companies have also laid out the injection of dossytaser polymer beam.
    In 2018, Fosun Pharmaceutical Holdings subsidiary Kaimao Bio obtained clinical approvals and related intellectual property rights for injection dossyla polymer beams in China from Huaplaxai Kaisheng with a rmb 15 million head payment and a milestone payment of up to RMB85 million, in order to enrich its product line and improve the market layout in the field of oncology treatment.
    addition, Guangdong Biomedics has received the CFDA-approved Dorsey polymer beam "Drug Clinical Trial Approval" in May 2018.
    as an improved new drug based on the anti-tumor drug dossin, injectable dossyta polymer beam has several well-known drug companies, after the market situation, it is worth looking forward to and attention.
    According to Seber blue observation, under the pressure and challenge of policy, in addition to the conventional business divestiture, enterprise spin-off, pipeline adjustment, pharmaceutical companies around research and development resources, innovative products, commercial channels, promotion team and other areas of cooperation is also increasing.
    title: Two well-known pharmaceutical companies have cooperated.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.